PDCD1 and esophageal cancer: The FDA has approved PD-1/PD-L1 checkpoint inhibitors for locally advanced or metastatic esophageal cancer patients, and PD-L1 (22C3) CPS score ≥ 10 is used as a companion diagnosis for its second-line treatment.